Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,500,000 shares, an increase of 5.6% from the March 31st total of 1,420,000 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily volume of 124,300 shares, the days-to-cover ratio is currently 12.1 days.

Wall Street Analysts Forecast Growth

GLPG has been the topic of several research analyst reports. StockNews.com cut Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Bank of America restated an “underperform” rating and issued a $31.00 target price (down from $41.00) on shares of Galapagos in a report on Thursday, March 28th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $38.00 target price on shares of Galapagos in a report on Monday, April 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $34.50.

Galapagos Stock Up 0.4 %

Shares of NASDAQ GLPG opened at $29.45 on Friday. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -12.86 and a beta of 0.27. The stock’s fifty day simple moving average is $32.25 and its 200 day simple moving average is $36.04. Galapagos has a 52-week low of $28.30 and a 52-week high of $45.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GLPG. Commonwealth Equity Services LLC grew its holdings in shares of Galapagos by 9.1% during the third quarter. Commonwealth Equity Services LLC now owns 6,000 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 500 shares in the last quarter. Monaco Asset Management SAM grew its holdings in shares of Galapagos by 3.8% during the third quarter. Monaco Asset Management SAM now owns 8,458 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 313 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Galapagos by 7,243.0% during the third quarter. Citigroup Inc. now owns 90,686 shares of the biotechnology company’s stock valued at $3,133,000 after buying an additional 89,451 shares in the last quarter. FMR LLC grew its holdings in shares of Galapagos by 0.7% during the third quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock valued at $149,176,000 after buying an additional 28,497 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Galapagos by 173.8% during the third quarter. Acadian Asset Management LLC now owns 19,149 shares of the biotechnology company’s stock valued at $661,000 after buying an additional 12,154 shares in the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.